NVCT

$0.00

(

+0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Nuvectis Pharma Inc

NASDAQ | NVCT

6.22

USD

+$0.00

(

+0.00%

)

At Close (As of Nov 28, 2025)

$155.23M

Market Cap

-

P/E Ratio

-1.37

EPS

$11.52

52 Week High

$4.44

52 Week Low

HEALTHCARE

Sector

NVCT Chart

Recent Chart
Price Action

NVCT Technicals

Tags:

NVCT Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -
Total Revenue $0
Cost Of Revenue -
Costof Goods And Services Sold -
Operating Income -$20M
Selling General And Administrative $6.9M
Research And Development $13M
Operating Expenses $20M
Investment Income Net -
Net Interest Income $847K
Interest Income $847K
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization -
Income Before Tax -$19M
Income Tax Expense -$19M
Interest And Debt Expense -
Net Income From Continuing Operations -$19M
Comprehensive Income Net Of Tax -
Ebit -$20M
Ebitda -$19M
Net Income -$19M

Revenue & Profitability

Earnings Performance

NVCT Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $19M
Total Current Assets $19M
Cash And Cash Equivalents At Carrying Value $19M
Cash And Short Term Investments $19M
Inventory -
Current Net Receivables -
Total Non Current Assets $0
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments -
Other Current Assets $74K
Other Non Current Assets -
Total Liabilities $8.9M
Total Current Liabilities $8.9M
Current Accounts Payable $2.5M
Deferred Revenue -
Current Debt -
Short Term Debt -
Total Non Current Liabilities $0
Capital Lease Obligations -
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total -
Other Current Liabilities $6.4M
Other Non Current Liabilities -
Total Shareholder Equity $9.7M
Treasury Stock -
Retained Earnings -$73M
Common Stock -
Common Stock Shares Outstanding $17M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$12M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization -
Capital Expenditures $0
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -
Cashflow From Financing $12M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$19M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -
Total Revenue $0
Cost Of Revenue -
Costof Goods And Services Sold -
Operating Income -$20M
Selling General And Administrative $6.9M
Research And Development $13M
Operating Expenses $20M
Investment Income Net -
Net Interest Income $847K
Interest Income $847K
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization -
Income Before Tax -$19M
Income Tax Expense -$19M
Interest And Debt Expense -
Net Income From Continuing Operations -$19M
Comprehensive Income Net Of Tax -
Ebit -$20M
Ebitda -$19M
Net Income -$19M

NVCT News

NVCT Profile

Nuvectis Pharma Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Nuvectis Pharma, Inc. (NVCT) is a biopharmaceutical company based in Fort Lee, New Jersey, specializing in the development of targeted small molecule therapies for cancer treatment. The company boasts a promising pipeline that utilizes cutting-edge drug discovery technologies, setting the stage for innovative solutions that aim to improve both the efficacy and tolerability of cancer therapies. With a strong commitment to precision medicine and scientific rigor, Nuvectis is well-positioned to make substantial advancements in oncology, presenting attractive growth opportunities for institutional investors in the biopharmaceutical arena.

LPTX
+368.57%
$2.05
VHAI
0.00%
$0.00
BYND
+19.00%
$1.02
KTTA
+54.72%
$1.64
VINE
+10.76%
$0.39
AMZE
+28.66%
$0.50
IPG
-1.95%
$24.57
TLRY
-20.11%
$0.82
BITF
+12.58%
$3.49
NVDA
-1.76%
$177.08
AXDX
-61.36%
$0.03
YGMZ
-10.65%
$0.10
INTC
+2.73%
$36.81
ADAP
-15.14%
$0.05
HOOD
+10.92%
$128.20
RUBI
-25.80%
$0.16
SOND
-23.45%
$0.12
RMBL
+60.50%
$3.21
LNW
-3.71%
$86.22
CLSK
+13.01%
$15.20
ADD
-25.47%
$0.05
ASST
+2.65%
$1.16
RIG
+6.17%
$4.30
SRM
+53.27%
$10.30
BIYA
+11.30%
$0.28
BAC
+0.97%
$52.99
INHD
+2.21%
$0.23
ONMD
+31.69%
$1.87
TWOH
0.00%
$0.00
WLGS
-5.57%
$0.04
BMNR
+6.26%
$33.72
MTSR
-0.35%
$70.50
CHR
-1.86%
$0.04
SNAP
+0.14%
$7.62
TSLA
+0.55%
$428.96
BMNU
+9.61%
$8.24
PCG
+1.78%
$16.01
CIFR
+10.05%
$21.07
PLUG
+2.09%
$2.02
ADTX
+19.42%
$3.75
AFMD
-34.94%
$0.18
MARA
+5.02%
$11.66
GPUS
-6.69%
$0.31
F
+0.65%
$13.27
DEFT
+11.51%
$1.55
WULF
+7.27%
$15.92
NIO
+0.36%
$5.48
KWM
+12.77%
$0.74
GRYP
-10.38%
$1.38
MODV
-25.22%
$0.43
AMCR
+1.29%
$8.62
ONDS
-2.81%
$8.00
GOOGL
-0.60%
$318.02
BTG
+3.13%
$4.61
SOFI
+3.18%
$29.39
VALE
+0.31%
$12.54
CRCL
+11.05%
$80.67
KDLY
+7.20%
$0.49
AAL
+0.60%
$14.01
DVLT
-6.33%
$1.99
SMX
+222.58%
$56.13
CSCO
-0.32%
$76.07
IBRX
+11.50%
$2.37
AG
+12.76%
$15.23
CAN
+12.59%
$1.03
IREN
-0.44%
$48.23
BTBT
+2.58%
$2.38
BURU
+5.44%
$0.23
SAND
-6.04%
$12.12
RIOT
+9.45%
$16.37
NGD
+5.86%
$8.30
LEN
+0.15%
$131.28
SHOT
-74.37%
$0.39
CRCA
+22.28%
$4.50
ZAPP
-46.30%
$0.15
HBI
-0.75%
$6.54
APLD
+7.21%
$26.74
PFE
+0.19%
$25.75
NVO
+1.38%
$49.38
GRAB
+2.67%
$5.46
GOOG
-0.73%
$317.92
AMD
+0.97%
$216.32
CRCG
+21.27%
$2.85
KO
+0.37%
$72.88
TMC
+14.32%
$6.66
C
+1.31%
$102.50
SNDK
+4.28%
$224.25
AGNC
-0.66%
$10.49
ABVE
+16.17%
$3.05
NEHC
+8.33%
$5.07
RIVN
+4.57%
$16.92
PLTR
+0.75%
$167.01
COMP
-0.76%
$10.42
NVTS
+6.83%
$8.91
CDE
+6.02%
$17.16
ACHR
+4.07%
$7.79
RF
+0.11%
$25.45
KEY
+0.16%
$18.40
MSTR
+2.73%
$180.44
DNN
+1.09%
$2.58
LPTX
+368.57%
$2.05
VHAI
0.00%
$0.00
BYND
+19.00%
$1.02
KTTA
+54.72%
$1.64
VINE
+10.76%
$0.39
AMZE
+28.66%
$0.50
IPG
-1.95%
$24.57
TLRY
-20.11%
$0.82
BITF
+12.58%
$3.49
NVDA
-1.76%
$177.08
AXDX
-61.36%
$0.03
YGMZ
-10.65%
$0.10
INTC
+2.73%
$36.81
ADAP
-15.14%
$0.05
HOOD
+10.92%
$128.20
RUBI
-25.80%
$0.16
SOND
-23.45%
$0.12
RMBL
+60.50%
$3.21
LNW
-3.71%
$86.22
CLSK
+13.01%
$15.20
ADD
-25.47%
$0.05
ASST
+2.65%
$1.16
RIG
+6.17%
$4.30
SRM
+53.27%
$10.30
BIYA
+11.30%
$0.28
BAC
+0.97%
$52.99
INHD
+2.21%
$0.23
ONMD
+31.69%
$1.87
TWOH
0.00%
$0.00
WLGS
-5.57%
$0.04
BMNR
+6.26%
$33.72
MTSR
-0.35%
$70.50
CHR
-1.86%
$0.04
SNAP
+0.14%
$7.62
TSLA
+0.55%
$428.96
BMNU
+9.61%
$8.24
PCG
+1.78%
$16.01
CIFR
+10.05%
$21.07
PLUG
+2.09%
$2.02
ADTX
+19.42%
$3.75
AFMD
-34.94%
$0.18
MARA
+5.02%
$11.66
GPUS
-6.69%
$0.31
F
+0.65%
$13.27
DEFT
+11.51%
$1.55
WULF
+7.27%
$15.92
NIO
+0.36%
$5.48
KWM
+12.77%
$0.74
GRYP
-10.38%
$1.38
MODV
-25.22%
$0.43
AMCR
+1.29%
$8.62
ONDS
-2.81%
$8.00
GOOGL
-0.60%
$318.02
BTG
+3.13%
$4.61
SOFI
+3.18%
$29.39
VALE
+0.31%
$12.54
CRCL
+11.05%
$80.67
KDLY
+7.20%
$0.49
AAL
+0.60%
$14.01
DVLT
-6.33%
$1.99
SMX
+222.58%
$56.13
CSCO
-0.32%
$76.07
IBRX
+11.50%
$2.37
AG
+12.76%
$15.23
CAN
+12.59%
$1.03
IREN
-0.44%
$48.23
BTBT
+2.58%
$2.38
BURU
+5.44%
$0.23
SAND
-6.04%
$12.12
RIOT
+9.45%
$16.37
NGD
+5.86%
$8.30
LEN
+0.15%
$131.28
SHOT
-74.37%
$0.39
CRCA
+22.28%
$4.50
ZAPP
-46.30%
$0.15
HBI
-0.75%
$6.54
APLD
+7.21%
$26.74
PFE
+0.19%
$25.75
NVO
+1.38%
$49.38
GRAB
+2.67%
$5.46
GOOG
-0.73%
$317.92
AMD
+0.97%
$216.32
CRCG
+21.27%
$2.85
KO
+0.37%
$72.88
TMC
+14.32%
$6.66
C
+1.31%
$102.50
SNDK
+4.28%
$224.25
AGNC
-0.66%
$10.49
ABVE
+16.17%
$3.05
NEHC
+8.33%
$5.07
RIVN
+4.57%
$16.92
PLTR
+0.75%
$167.01
COMP
-0.76%
$10.42
NVTS
+6.83%
$8.91
CDE
+6.02%
$17.16
ACHR
+4.07%
$7.79
RF
+0.11%
$25.45
KEY
+0.16%
$18.40
MSTR
+2.73%
$180.44
DNN
+1.09%
$2.58
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.